• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Berkeley Lights Reports Second Quarter 2022 Financial Results

    8/9/22 4:02:00 PM ET
    $BLI
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $BLI alert in real time by email

    Company outlines near-term strategic plan to generate positive operating cashflow by early 2025

    EMERYVILLE, Calif., Aug. 9, 2022 /PRNewswire/ -- Berkeley Lights, Inc. (NASDAQ:BLI), a leader in digital cell biology, today reported financial results for the quarter ended June 30, 2022.

    (PRNewsfoto/Berkeley Lights)

    Financial Highlights
    • Delivered total revenue of $19.2 million for the second quarter of 2022, representing a decrease of 1% compared to the second quarter of 2021
    • Achieved recurring revenue of $5.9 million, an increase of 50% year over year
    • Delivered gross margin of 67% for the second quarter of 2022 compared to 66% for the second quarter of 2021
    • Reduced operating costs through a global workforce reduction of approximately 12% in July 2022 and optimized business structure and processes to decrease cash burn to approximately $30 million in 2023
    Business update

    During the quarter, Berkeley Lights management completed a comprehensive assessment of the business and initiated a near-term strategic plan aligned to five pillars where the Company will:

    • Generate positive operating cash flow by early 2025;
    • Prioritize R&D return on investment through increased focus and rigor on development initiatives;
    • Deliver consistent commercial execution through a new sales structure and enhanced product portfolio and pricing strategy;
    • Build a world-class leadership team with a proven track record in profitably scaling life sciences tools and services companies; and
    • Evaluate M&A opportunities that will accelerate profitable growth and leverage our current cost structure.

    "In the second quarter, we made meaningful progress to transform Berkeley Lights from a technology platform company into a growing, profitable and sustainable life sciences tools and services company," said Dr. Siddhartha Kadia, chief executive officer of Berkeley Lights. "We are confident and excited about the opportunities ahead for Berkeley Lights and our ability to advance our strategy to create value for our shareholders."

    Second Quarter 2022 Financial Results





    Three months ended June 30,

    (in thousands, except per share data)

    2022

    2021



    (unaudited)

    (unaudited)

    Revenue

    $              19,150

    $              19,250

    Gross profit

    $              12,926

    $              12,728

    Gross margin %

    67 %

    66 %

    Operating expenses

    $              38,473

    $              30,577

    Loss from operations

    $             (25,547)

    $             (17,849)

    Net loss

    $             (25,747)

    $             (18,154)

    Net loss attributable to common stockholders per share, basic and diluted

    $                 (0.38)

    $                 (0.27)

    Total stock-based compensation

    $                6,565

    $                5,629

    2022 Guidance Outlook

    Berkeley Lights now expects full-year 2022 revenue to be approximately in line with full-year 2021 revenue as the Company works to realign the business around its new strategic objectives.

    Webcast and Conference Call Information

    Berkeley Lights will host a conference call to discuss the second quarter 2022 financial results after market close on Tuesday, August 9, 2022 at 1:30 p.m. Pacific Time/4:30 p.m. Eastern Time. A webcast of the conference call can be accessed at http://investors.berkeleylights.com. The webcast will be archived and available for replay for at least 90 days after the event.

    About Berkeley Lights

    Berkeley Lights is a leading digital cell biology company focused on enabling and accelerating the rapid development and commercialization of biotherapeutics and other cell-based products for our customers. The Berkeley Lights Platform captures deep phenotypic, functional, and genotypic information for thousands of single cells in parallel and can also deliver the live biology customers desire in the form of the best cells. Our platform is a fully integrated, end-to-end solution, comprising proprietary consumables, including our OptoSelect® chips and reagent kits, advanced automation systems, and application software. We developed the Berkeley Lights Platform to provide the most advanced environment for rapid functional characterization of single cells at scale, the goal of which is to establish an industry standard for our customers throughout their cell-based product value chain.            

    Berkeley Lights' Beacon and Lightning systems and Culture Station instrument are: FOR RESEARCH USE ONLY. Not for use in diagnostic procedures.

    Forward Looking Statements

    This press release contains forward-looking statements that are based on management's beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. 

    In some cases, you can identify forward-looking statements by the words "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

    Berkeley Lights, Inc.

    Condensed Consolidated Statements of Operations (Unaudited)

    (In thousands, except share and per share data)





    Three months ended June 30,



    Six months ended June 30,



    2022



    2021



    2022



    2021

















    Revenue:















    Product revenue

    $        9,468



    $      13,021



    $      19,242



    $      26,554

    Service revenue

    9,682



    6,229



    20,114



    11,324

    Total revenue

    19,150



    19,250



    39,356



    37,878

    Cost of sales:















    Product cost of sales

    2,614



    3,332



    5,309



    7,035

    Service cost of sales

    3,610



    3,190



    7,294



    5,664

    Total cost of sales

    6,224



    6,522



    12,603



    12,699

    Gross profit

    12,926



    12,728



    26,753



    25,179

    Operating expenses:















    Research and development

    18,178



    13,535



    35,751



    26,562

    General and administrative

    13,024



    11,725



    24,740



    20,692

    Sales and marketing

    7,271



    5,317



    13,082



    10,923

    Total operating expenses

    38,473



    30,577



    73,573



    58,177

    Loss from operations

    (25,547)



    (17,849)



    (46,820)



    (32,998)

    Other income (expense):















    Interest expense

    (227)



    (356)



    (451)



    (710)

    Interest income

    53



    43



    87



    109

    Other income (expense), net

    (22)



    34



    35



    53

    Loss before income taxes

    (25,743)



    (18,128)



    (47,149)



    (33,546)

    Provision for income taxes

    4



    26



    24



    43

    Net loss

    $    (25,747)



    $    (18,154)



    $    (47,173)



    $    (33,589)

















    Net loss attributable to common stockholders per share, basic and diluted

    $        (0.38)



    $        (0.27)



    $        (0.70)



    $        (0.51)

    Weighted-average shares used in calculating net loss per share, basic and diluted

    67,985,664



    66,790,755



    67,842,372



    66,029,307

     

    Berkeley Lights, Inc.

    Condensed Consolidated Balance Sheets

    (In thousands)



    Assets

    June 30,

    2022



    December 31,

    2021



    (unaudited)





    Current assets:







    Cash and cash equivalents

    $        143,024



    $       178,096

    Short-term marketable securities

    9,361



    —

    Trade accounts receivable

    13,815



    25,942

    Inventory

    15,664



    14,547

    Prepaid expenses and other current assets

    10,606



    11,985

    Total current assets

    192,470



    230,570

    Restricted cash

    —



    270

    Property and equipment, net

    29,317



    27,992

    Operating lease right-of-use assets

    24,522



    26,060

    Other assets

    2,397



    2,361

    Total assets

    $        248,706



    $       287,253

    Liabilities and Stockholders' Equity







    Current liabilities:







    Trade accounts payable

    $            8,499



    $           8,198

    Accrued expenses and other current liabilities

    11,945



    12,425

    Deferred revenue

    8,694



    12,128

    Total current liabilities

    29,138



    32,751

    Notes payable

    19,794



    19,762

    Deferred revenue, net of current portion

    1,221



    2,187

    Lease liability, long-term

    24,137



    24,337

    Total liabilities

    74,290



    79,037

    Stockholders' equity:







        Common stock

    4



    4

    Additional paid-in capital

    485,212



    471,820

    Accumulated deficit

    (310,781)



    (263,608)

    Accumulated other comprehensive loss

    (19)



    —

    Total stockholders' equity

    174,416



    208,216

    Total liabilities and stockholders' equity

    $        248,706



    $       287,253

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/berkeley-lights-reports-second-quarter-2022-financial-results-301602896.html

    SOURCE Berkeley Lights, Inc.

    Get the next $BLI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BLI

    DatePrice TargetRatingAnalyst
    8/10/2022$10.00 → $5.00Equal-Weight → Underweight
    Morgan Stanley
    8/10/2022Buy → Neutral
    BTIG Research
    8/10/2022$12.00 → $8.00Overweight → Neutral
    JP Morgan
    3/2/2022Outperform
    Cowen
    2/25/2022$20.00 → $14.00Equal-Weight
    Morgan Stanley
    2/15/2022$36.00 → $20.00Equal-Weight
    Morgan Stanley
    1/6/2022$61.00 → $12.00Buy → Hold
    Stifel
    1/6/2022Outperform → Mkt Perform
    William Blair
    More analyst ratings

    $BLI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Berkeley Lights Inc. (Amendment)

      SC 13G/A - Bruker Cellular Analysis, Inc. (0001689657) (Subject)

      2/8/24 5:58:45 PM ET
      $BLI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G filed by Berkeley Lights Inc.

      SC 13G - PhenomeX Inc. (0001689657) (Subject)

      8/28/23 5:04:18 PM ET
      $BLI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Berkeley Lights Inc. (Amendment)

      SC 13G/A - PhenomeX Inc. (0001689657) (Subject)

      5/5/23 11:52:59 AM ET
      $BLI
      Medicinal Chemicals and Botanical Products
      Health Care

    $BLI
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $BLI
    Financials

    Live finance-specific insights

    See more

    $BLI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $BLI
    SEC Filings

    See more

    $BLI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors

      Contineum Therapeutics, Inc. (NASDAQ:CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Sarah Boyce, President and Chief Executive Officer of Avidity Biosciences, Inc. (NASDAQ:RNA), as an independent member of its Board of Directors. Ms. Boyce brings over 25 years of global commercial and clinical development expertise in the life sciences industry to Contineum's board. Ms. Boyce has extensive expertise in global pharmaceut

      6/24/24 4:05:00 PM ET
      $CTNM
      $IONS
      $NVS
      $RNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals
      Medicinal Chemicals and Botanical Products
    • Berkeley Lights Completes Acquisition of IsoPlexis Forming PhenomeX, the Functional Cell Biology Company

      PhenomeX to begin trading under symbol (NASDAQ:CELL) EMERYVILLE, Calif., March 21, 2023 /PRNewswire/ -- Berkeley Lights, Inc. (NASDAQ:BLI), a life sciences tools company, today announced that it has completed its previously announced acquisition of IsoPlexis Corporation (NASDAQ:ISO), a company empowering labs to leverage the cells and proteome changing the course of human health. The newly combined company has been renamed PhenomeX and its common stock will begin trading on Nasdaq under the ticker symbol "CELL" at market open tomorrow. PhenomeX is positioned to be the leading

      3/21/23 8:02:00 AM ET
      $BLI
      $ISO
      Medicinal Chemicals and Botanical Products
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
    • Berkeley Lights Reports Fourth Quarter and Full Year 2022 Financial Results

      EMERYVILLE, Calif., Feb. 23, 2023 /PRNewswire/ -- Berkeley Lights, Inc. (NASDAQ:BLI), a life sciences tools company, today reported financial results for the fourth quarter and full year ended December 31, 2022. Recent Highlights Achieved revenue of $78.6 million for the full year 2022, representing an 8% decrease over the prior year;Announced the acquisition agreement of IsoPlexis to create a premier functional cell biology company, PhenomeX, when the merger closes, would accelerate the transformation of Berkeley Lights from a technology platform company into a growing, profi

      2/23/23 4:23:00 PM ET
      $BLI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Berkeley Lights Reports Fourth Quarter and Full Year 2022 Financial Results

      EMERYVILLE, Calif., Feb. 23, 2023 /PRNewswire/ -- Berkeley Lights, Inc. (NASDAQ:BLI), a life sciences tools company, today reported financial results for the fourth quarter and full year ended December 31, 2022. Recent Highlights Achieved revenue of $78.6 million for the full year 2022, representing an 8% decrease over the prior year;Announced the acquisition agreement of IsoPlexis to create a premier functional cell biology company, PhenomeX, when the merger closes, would accelerate the transformation of Berkeley Lights from a technology platform company into a growing, profi

      2/23/23 4:23:00 PM ET
      $BLI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Berkeley Lights to Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023

      EMERYVILLE, Calif., Feb. 13, 2023 /PRNewswire/ -- Berkeley Lights, Inc. (NASDAQ:BLI), a life sciences tools company, today announced that the Company will be reporting financial results for the fourth quarter and full year 2022 after market on Thursday, February 23, 2023. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.   Live audio of the webcast will be available on the "Investors" section of the Company's website at www.berkeleylights.com. The webcast will be archived and available for replay

      2/13/23 4:30:00 PM ET
      $BLI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Berkeley Lights Reports Preliminary Full Year 2022 Revenue Results

      EMERYVILLE, Calif., Jan. 9, 2023 /PRNewswire/ -- Berkeley Lights, Inc. (NASDAQ:BLI), a life sciences tools company, today announced preliminary unaudited revenue results for the full year ended December 31, 2022. Total revenue for the full year 2022 is expected to be in the range of $78.0 million to $78.5 million, compared to $85.4 million in 2021. Results were lower-than-expected due to a delay in several Beacon® platform placements, which are now expected in 2023, and lower revenue from partnership and services contracts. During fourth quarter 2022, we observed a tightening

      1/9/23 4:02:00 PM ET
      $BLI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Berkeley Lights downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Berkeley Lights from Equal-Weight to Underweight and set a new price target of $5.00 from $10.00 previously

      8/10/22 9:27:59 AM ET
      $BLI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Berkeley Lights downgraded by BTIG Research

      BTIG Research downgraded Berkeley Lights from Buy to Neutral

      8/10/22 7:24:20 AM ET
      $BLI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Berkeley Lights downgraded by JP Morgan with a new price target

      JP Morgan downgraded Berkeley Lights from Overweight to Neutral and set a new price target of $8.00 from $12.00 previously

      8/10/22 6:23:47 AM ET
      $BLI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 15-12G filed by Berkeley Lights Inc.

      15-12G - Bruker Cellular Analysis, Inc. (0001689657) (Filer)

      10/12/23 9:00:26 AM ET
      $BLI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form POSASR filed by Berkeley Lights Inc.

      POSASR - Bruker Cellular Analysis, Inc. (0001689657) (Filer)

      10/2/23 5:16:24 PM ET
      $BLI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form S-8 POS filed by Berkeley Lights Inc.

      S-8 POS - Bruker Cellular Analysis, Inc. (0001689657) (Filer)

      10/2/23 5:06:56 PM ET
      $BLI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Kadia Siddhartha returned 1,240,689 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Bruker Cellular Analysis, Inc. (0001689657) (Issuer)

      10/3/23 3:42:49 PM ET
      $BLI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Chiminski John R returned 112,465 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Bruker Cellular Analysis, Inc. (0001689657) (Issuer)

      10/3/23 3:41:09 PM ET
      $BLI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Silvester Peter returned 64,596 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Bruker Cellular Analysis, Inc. (0001689657) (Issuer)

      10/3/23 3:32:22 PM ET
      $BLI
      Medicinal Chemicals and Botanical Products
      Health Care

    $BLI
    Leadership Updates

    Live Leadership Updates

    See more
    • Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors

      Contineum Therapeutics, Inc. (NASDAQ:CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Sarah Boyce, President and Chief Executive Officer of Avidity Biosciences, Inc. (NASDAQ:RNA), as an independent member of its Board of Directors. Ms. Boyce brings over 25 years of global commercial and clinical development expertise in the life sciences industry to Contineum's board. Ms. Boyce has extensive expertise in global pharmaceut

      6/24/24 4:05:00 PM ET
      $CTNM
      $IONS
      $NVS
      $RNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals
      Medicinal Chemicals and Botanical Products
    • Berkeley Lights Announces Appointment of Scott Chaplin as Chief Legal Officer

      EMERYVILLE, Calif., Sept. 19, 2022 /PRNewswire/ -- Berkeley Lights, Inc. (NASDAQ:BLI), a leader in digital cell biology, today announced that Scott Chaplin has been named the Company's chief legal officer and corporate secretary, effective immediately. Mr. Chaplin will have overall responsibility for the corporate legal function, including contracts, governance, compliance and management of its extensive intellectual property and patent portfolio. As chief legal officer, he will serve as an adviser to the chief executive officer (CEO), Board of Directors, and senior management members.

      9/19/22 8:43:00 AM ET
      $BLI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Berkeley Lights Announces Appointment of Dr. Rolando Brawer as Executive Vice President, Strategy & Corporate Development

      EMERYVILLE, Calif., Aug. 1, 2022 /PRNewswire/ -- Berkeley Lights, Inc. (NASDAQ:BLI), a leader in digital cell biology, today announced that Rolando Brawer, Ph.D. has been named executive vice president, Strategy & Corporate Development, effective immediately. In this newly created role, Dr. Brawer will lead Berkeley Lights' strategy and corporate development functions and support the Company's growth strategy through identification, assessment and execution of potential mergers, acquisitions, investments, licensing agreements, joint ventures and more. "We are thrilled to welco

      8/1/22 8:35:00 AM ET
      $BLI
      Medicinal Chemicals and Botanical Products
      Health Care